Separately, B. Riley reduced their price objective on MediciNova from $11.00 to $6.00 in a report on Monday, January 24th.
Shares of NASDAQ:MNOV opened at $2.49 on Tuesday. MediciNova has a 1-year low of $2.09 and a 1-year high of $5.09. The business has a fifty day moving average price of $2.67 and a 200-day moving average price of $2.70.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MNOV. Marshall Wace LLP bought a new stake in MediciNova in the 1st quarter worth about $54,000. Morgan Stanley boosted its position in MediciNova by 1,530.3% in the second quarter. Morgan Stanley now owns 58,577 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 54,984 shares during the last quarter. Bank of America Corp DE boosted its position in MediciNova by 120.7% in the second quarter. Bank of America Corp DE now owns 168,763 shares of the biopharmaceutical company’s stock worth $717,000 after purchasing an additional 92,301 shares during the last quarter. BlackRock Inc. boosted its position in MediciNova by 1.6% in the third quarter. BlackRock Inc. now owns 1,145,970 shares of the biopharmaceutical company’s stock worth $4,344,000 after purchasing an additional 18,048 shares during the last quarter. Finally, Barclays PLC boosted its position in MediciNova by 52.2% in the third quarter. Barclays PLC now owns 154,016 shares of the biopharmaceutical company’s stock worth $584,000 after purchasing an additional 52,856 shares during the last quarter. Institutional investors own 15.57% of the company’s stock.
About MediciNova (Get Rating)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
- Get a free copy of the StockNews.com research report on MediciNova (MNOV)
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.